Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer's disease: Possible interactions between amyloid-β and these lipids

Journal of Alzheimer's Disease

Volumn 50, Issue 2, 2016, Pages 527-537

  Yamashita, Shinji ^a,b   Kiko, Takehiro ^b   Fujiwara, Hironori ^b,c   Hashimoto, Michio ^d   Nakagawa, Kiyotaka ^b   Kinoshita, Mikio ^a   Furukawa, Katsutoshi ^b   Arai, Hiroyuki ^b   Miyazawa, Teruo ^b  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; amyloid ; phospholipid hydroperoxide; plasmalogen

Indexed keywords

AMYLOID BETA PROTEIN; DOCOSAHEXAENOIC ACID; PHOSPHOLIPID; PHOSPHOLIPID HYDROPEROXIDE; PLASMALOGEN; UNCLASSIFIED DRUG; HYDROGEN PEROXIDE; PHOSPHATIDYLCHOLINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN LIPID INTERACTION; BLOOD;

AGED; AMYLOID BETA-PEPTIDES; FEMALE; HUMANS; HYDROGEN PEROXIDE; MALE; PHOSPHATIDYLCHOLINES; PLASMALOGENS;

EID: 84970929768     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150640     Document Type: Article

References (67)

1. Younkin SG. (1995). Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol 37, 287-288
2. de la Torre JC. (2004). Is Alzheimer's disease a neurodegenerative or a vascular disorder'. Data, dogma, and dialectics. Lancet Neurol 3, 184-190
3. Selkoe DJ. (2002). Alzheimer's disease is a synaptic failure. Science 298, 789-791
4. Wirths O, Multhaup G, Bayer TA. (2004). A modified-βAmyloid hypothesis: Intraneuronal accumulation of the-β amyloid peptide-the first step of a fatal cascade. J Neurochem 91, 513-520
5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319
6. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, DeDeyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H. (1999). Improved discrimination of AD patients using-β amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562
7. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. (2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis 39, 253-259
8. Olazaŕan J, Gil-de-Gómez L, Rodríguez-Martín A, Valentí-Soler M, Frades-Payo B, Marín-Muñoz J, Antúnez C, Frank-García A, Acedo-Jiménez C, Morĺan-Gracia L, Petidier-Torregrossa R, Guisasola MC, Bermejo-Pareja F, Sánchez-Ferro Á , Pérez-Martínez DA, Manzano-Palomo S, Farquhar R, Rábano A, Calero M. (2015). A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. J Alzheimers Dis 45, 1157-1173
9. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. (2002). Brain to plasma amyloid-α efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267
10. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. (1996). Secreted amyloid-βprotein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870
11. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. (2000). Plasma and cerebrospinal fluid levels of amyloidβproteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105
12. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. (2006). Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: A prospective case-cohort study. Lancet Neurol 5, 655-660
13. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. (2007). Association of low plasma Aβ42/Aα40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362
14. Mattson MP, Begley JG, Mark RJ, Furukawa K. (1997). Aβ25-35 induces rapid lysis of red blood cells: Contrast withAβ1-42 and examination of underlying mechanisms. Brain Res 771, 147-153
15. Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM. (2008). Do red blood cell-β-Amyloid interactions alter oxygen delivery in Alzheimer's disease?. Adv Exp Med Biol 614, 29-35
16. Jayakumar R, Kusiak JW, Chrest FJ, Demehin AA, Murali J, Wersto RP, Nagababu E, Ravi L, Rifkind JM. (2003). Red cell perturbations by amyloid-β protein. Biochim Biophys Acta 1622, 20-28
17. Nakagawa K, Kiko T, Miyazawa T, Sookwong P, Tsuduki T, Satoh A, Miyazawa T. (2011). Amyloid-β induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett 585, 1249-1254
18. Nakagawa K, Kiko T, Kuriwada S, Miyazawa T, Kimura F, Miyazawa T. (2011). Amyloidβinduces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci Biotechnol Biochem 75, 2030-2033
19. Kiko T, Nakagawa K, Tsuduki T, Suzuki T, Arai H, Miyazawa T. (2012). Significance of lutein in red blood cells of Alzheimer's disease patients. J Alzheimers Dis 28, 593-600
20. Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, Miyazawa T. (2012). Amyloidβlevels in human red blood cells. PLoS One 7, e49620
21. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. (1995). Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 698, 223-226
22. Wells K, Farooqui AA, Liss L, Horrocks LA. (1995). Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20, 1329-1333
23. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. (1999). Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58, 740-747
24. Martin V, Fabelo N, Santpere G, Puig B, Marin R, Ferrer I, Diaz M. (2010). Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 19, 489-502
25. Glaser PE, Gross RW. (1994). Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry 33, 5805-5812
26. Miyazawa T Kanno S, Eitsuka T, Nakagawa K. (2006). Plasmalogen: A short review and newly-discovered functions. In Dietary Fats and Risk of Chronic Disease, Yanagita Y, Knapp HR, Huang YS, eds. AOCS Publishing, pp. 196-202
27. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. (2007). Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48, 2485-2498
28. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, Goodenowe DB. (2010). Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35, 59-62
29. Yamashita S, Honjo A, Aruga M, Nakagawa K, Miyazawa T. (2014). Preparation of marine plasmalogen and selective identification of molecular species by LC-MS/MS. J Oleo Sci 63, 423-430
30. Rose HG, Oklander M. (1965). Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res 6, 428-431
31. Folch J, Lees M, Sloane Stanley GH. (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509
32. Bartlett GR. (1959). Phosphorus assay in column chromatography. J Biol Chem 234, 466-468
33. Yamashita S, Abe A, Nakagawa K, Kinoshita M, Miyazawa T. (2014). Separation and detection of plasmalogen in marine invertebrates by high-performance liquid chromatography with evaporative light-scattering detection. Lipids 49, 1261-1273
34. Maulik N, Bagchi D, Jones R, Cordis G, Das DK. (1993). Identification and characterization of plasmalogen fatty acids in swine heart. J Pharm Biomed Anal 11, 1151-1156
35. Shoji N, Nakagawa K, Asai A, Fujita I, Hashiura A, Nakajima Y, Oikawa S, Miyazawa T. (2010). LC-MS/MS analysis of carboxymethylated and carboxyethylated phosphatidylethanolamines in human erythrocytes and blood plasma. J Lipid Res 51, 2445-2453
36. Ikeda S, Tohyama T, Yoshimura H, Hamamura K, Abe K, Yamashita K. (2003). Dietary-β tocopherol decreases-β tocotrienol but not-β tocotrienol concentration in rats. J Nutr 133, 428-434
37. Suemoto T, Okamura N, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Kudo Y, Sawada T. (2004). In vivo labeling of amyloid with BF-108. Neurosci Res 48, 65-74
38. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. (2004). Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 189, 380-392
39. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. (1996). RAGE and amyloid-α peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691
40. Pratico D, Delanty N. (2000). Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. Am J Med 109, 577-585
41. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. (2003). Plasma Aα40 and Aβ42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61, 1185-1190
42. Zlokovic BV. (2004). Clearing amyloid through the bloodbrain barrier. J Neurochem 89, 807-811
43. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. (2010). Peripherally applied A-βcontaining inoculates induce cerebral-β amyloidosis. Science 330, 980-982
44. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. (2011). Meta-Analysis of plasma amyloid-α levels in Alzheimer's disease. J Alzheimers Dis 26, 365-375
45. Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T. (2010). Plasma Aβ42 and Aα40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81, 1123-1127
46. Miyazawa T Suzuki T, Yasuda K, Fujimoto K, Meguro K, Sasaki H. (1992). Accumulation of phospholipid hydroperoxides in red blood cell membranes in Alzheimer disease. In Oxygen Radicals, Yagi K, Kondo M, Niki E, Yoshikawa T, eds. Elsevier, pp. 327-330
47. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 32, 763-777
48. Farooqui AA, Horrocks LA. (1998). Plasmalogen-selective phospholipaseA2 and its involvement in Alzheimer's disease. Biochem Soc Trans 26, 243-246
49. Farooqui AA, Horrocks LA. (2006). Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist 12, 245-260
50. Lee JC, Simonyi A, Sun AY, Sun GY. (2011). Phospholipases A2 and neural membrane dynamics: Implications for Alzheimer's disease. J Neurochem 116, 813-819
51. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D. (2010). Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 5, e12538
52. Kou J, Kovacs GG, Hoftberger R, Kulik W, Brodde A, Forss-Petter S, Honigschnabl S, Gleiss A, Brugger B, Wanders R, Just W, Budka H, Jungwirth S, Fischer P, Berger J. (2011). Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 122, 271-283
53. Rothhaar TL, Grosgen S, Haupenthal VJ, Burg VK, Hundsdorfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO. (2012). Plasmalogens inhibit APP processing by directly affecting-β secretase activity in Alzheimer's disease. ScientificWorldJournal 2012, 141240
54. Onodera T, Futai E, Kan E, Abe N, Uchida T, Kamio Y, Kaneko J. (2015). Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on-β secretase activity. J Biochem 157, 301-309
55. Kinoshita M, Oikawa S, Hayasaka K, Sekikawa A, Nagashima T, Toyota T, Miyazawa T. (2000). Age-related increases in plasma phosphatidylcholine hydroperoxide concentrations in control subjects and patients with hyperlipidemia. Clin Chem 46, 822-828
56. Nagashima T, Oikawa S, Hirayama Y, Tokita Y, Sekikawa A, Ishigaki Y, Yamada R, Miyazawa T. (2002). Increase of serum phosphatidylcholine hydroperoxide dependent on glycemic control in type 2 diabetic patients. Diabetes Res Clin Pract 56, 19-25
57. Suzuki K, Nakagawa K, Miyazawa T. (2014). Augmentation of blood lipid glycation and lipid oxidation in diabetic patients. Clin Chem Lab Med 52, 47-52
58. Asai A, Okajima F, Nakajima Y, Nagao M, Nakagawa K, Miyazawa T, Oikawa S. (2011). Involvement of Rac GTPase activation in phosphatidylcholine hydroperoxideinduced THP-1 cell adhesion to ICAM-1. Biochem Biophys Res Commun 406, 273-277
59. Lan J, Liu J, Zhao Z, Xue R, Zhang N, Zhang P, Zhao P, Zheng F, Sun X. (2015). The peripheral blood of Aα binding RBC as a biomarker for diagnosis of Alzheimer's disease. Age Ageing 44, 458-464
60. Weisser M, Vieth M, Stolte M, Riederer P, Pfeuffer R, Leblhuver F, Spiteller G. (1997). Dramatic increase of-β hydroxyaldehydes derived from plasmalogens in the aged human brain. Chem Phys Lipids 90, 135-142
61. Braverman NE, Moser AB. (2012). Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 1822, 1442-1452
62. Liu YH, Wang YR, Xiang Y, Zhou HD, Giunta B, Mañucat-Tan NB, Tan J, Zhou XF, Wang YJ. (2015). Clearance of amyloid-beta in Alzheimer's disease: Shifting the action site from center to periphery. Mol Neurobiol 51, 1-7
63. Kato S, Nakagawa K, Suzuki Y, Asai A, Nagao M, Nagashima K, Oikawa S, Miyazawa T. (2015). Liquid chromatography-Tandem mass spectrometry determination of human plasma 1-palmitoyl-2-hydroperoxyoctadecadienoylphosphatidylcholine isomers via promotion of sodium adduct formation. Anal Biochem 471, 51-60
64. Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS. (2011). Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 24, 507-517
65. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ. (2014). Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418
66. Nishimukai M, Wakisaka T, Hara H. (2003). Ingestion of plasmalogen markedly increased plasmalogen levels of blood plasma in rats. Lipids 38, 1227-1235
67. Yamashita S, Kannno S, Nakagawa K, Kinoshita M, Miyazawa T. (2015). Extrinsic plasmalogen suppresses neuronal apoptosis in mouse neuroblastoma Neuro-2A cells: Importance of plasmalogen molecular species. RSC Adv 5, 61012-61020